Inventor · disambiguated record
Yuguang Wang
Also filed as: WANG YUGUANG
31 granted patents·18 pending applications·564 citations·filing 1996–2025
96Inventor score
Files withSCHERING CORP17GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD14CYCLERION THERAPEUTICS INC5WANG YUGUANG3CHACKALAMANNIL SAMUEL2
Top patents by PatentIndex Score
49 records- 0198US6821978B2Xanthine phosphodiesterase V inhibitorsSCHERING CORP·Filed 2001·Granted Nov 23, 2004·140 cites·34 claims
- 0296US5977138AEther muscarinic antagonistsSCHERING CORP·Filed 1997·Granted Nov 2, 1999·99 cites·19 claims
- 0394US11708361B2Processes and intermediates for the preparation of soluble guanylate cyclase stimulatorsCYCLERION THERAPEUTICS INC·Filed 2021·Granted Jul 25, 2023·2 cites·14 claims
- 0493US12030874B2Processes and intermediates for the preparation of soluble guanylate cyclase stimulatorsCYCLERION THERAPEUTICS INC·Filed 2023·Granted Jul 9, 2024·1 cites·20 claims
- 0593US5889006AMuscarinic antagonistsSCHERING CORP·Filed 1996·Granted Mar 30, 1999·123 cites·18 claims
- 0692US7304078B2Thrombin receptor antagonistsSCHERING CORP·Filed 2003·Granted Dec 4, 2007·43 cites·67 claims
- 0792US6969719B2Polycyclic guanine phosphodiesterase V inhibitorsSCHERING CORP·Filed 2002·Granted Nov 29, 2005·59 cites·26 claims
- 0887US12275724B2Processes and intermediates for the preparation of soluble guanylate cyclase stimulatorsCYCLERION THERAPEUTICS INC·Filed 2024·Granted Apr 15, 2025·0 cites·4 claims
- 0987US11274096B2Processes and intermediates for the preparation of soluble guanylate cyclase stimulatorsCYCLERION THERAPEUTICS INC·Filed 2019·Granted Mar 15, 2022·2 cites·22 claims
- 1086US7713999B2Thrombin receptor antagonistsSCHERING CORP·Filed 2007·Granted May 11, 2010·8 cites·46 claims
- 1184US11078192B2Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereofGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2017·Granted Aug 3, 2021·2 cites·21 claims
- 1282US8933113B2Mineralocorticoid receptor antagonistsCRESPO ALEJANDRO·Filed 2012·Granted Jan 13, 2015·11 cites·17 claims
- 1382US6043255AMuscarinic antagonistsSCHERING CORP·Filed 1999·Granted Mar 28, 2000·50 cites·16 claims
- 1481US7531544B2Xanthine phosphodiesterase V inhibitorsSCHERING CORP·Filed 2007·Granted May 12, 2009·2 cites·3 claims
- 1580US7888369B2Oxazoloisoquinoline derivatives as thrombin receptor antagonistsSCHERING CORP·Filed 2006·Granted Feb 15, 2011·4 cites·8 claims
- 1679US7442712B2Constrained himbacine analogs as thrombin receptor antagonistsSCHERING CORP·Filed 2005·Granted Oct 28, 2008·6 cites·15 claims
- 1779US2025361228A1Processes and intermediates for the preparation of soluble guanylate cyclase stimulatorsCYCLERION THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1872US7268141B2Xanthine phosphodiesterase V inhibitorsSCHERING CORP·Filed 2004·Granted Sep 11, 2007·4 cites·22 claims
- 1969US8153664B2Bicyclic and tricyclic derivatives as thrombin receptor antagonistsCHACKALAMANNIL SAMUEL·Filed 2007·Granted Apr 10, 2012·1 cites·6 claims
- 2067US2022315525A1Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and applicationGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2166US11384048B2Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and applicationGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2018·Granted Jul 12, 2022·0 cites·19 claims
- 2265US10494378B2Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereofGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2016·Granted Dec 3, 2019·1 cites·18 claims
- 2362US6831089B2Muscarinic antagonistsSCHERING CORP·Filed 2002·Granted Dec 14, 2004·1 cites·15 claims
- 2461US2005075349A1Xanthine phosphodiesterase V inhibitorsSCHERING CORP·Filed 2004·Application pending·0 cites
- 2560US2004229885A1Xanthine phosphodiesterase V inhibitorsSCHERING CORP·Filed 2004·Application pending·0 cites
- 2659US2007270439A1Thrombin receptor antagonistsSCHERING CORP·Filed 2007·Application pending·0 cites
- 2759US2005182077A1Xanthine phosphodiesterase V inhibitorsSCHERING CORP·Filed 2005·Application pending·0 cites
- 2858US12473300B2Thienopyrimidine derivative and preparation method thereforGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2021·Granted Nov 18, 2025·0 cites·16 claims
- 2957US10611770B2Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereofGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2019·Granted Apr 7, 2020·0 cites·19 claims
- 3057US2025073358A1Aromatic vinyl compound, metal complex thereof, and preparation method therefor and use thereofSHANGHAI MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 3156US12428369B2Crystal form of aromatic vinyl derivatives, and preparation method therefor and use thereofGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2021·Granted Sep 30, 2025·0 cites·21 claims
- 3253US10259816B2Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereofGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2016·Granted Apr 16, 2019·0 cites·19 claims
- 3353US9403807B2Mineralocorticoid receptor antagonistsMERCK SHARP & DOHME·Filed 2014·Granted Aug 2, 2016·0 cites·5 claims
- 3453US2007254952A1Cannabinoid receptor modulatorsWANG YUGUANG·Filed 2007·Application pending·0 cites
- 3552US2023046904A1Combination of small molecule inhibitor of the pd-1/pd-l1 interaction and anti-pd-1 antibody for treating cancerGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 3650US2023331675A1Aromatic ethylene compound and preparation method therefor, and intermediate, pharmaceutical composition, and application thereofGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3750US2022168268A1Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of sameGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 3848US2021387941A1Diphenyl-like Compound, Intermediate Thereof, Preparation Method Therefor, Pharmaceutical Composition Thereof And Uses ThereofSHANGHAI MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 3947US11352368B2Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereofGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2019·Granted Jun 7, 2022·0 cites·16 claims
- 4047US2008085923A1Thrombin Receptor Antagonists Based On The Modified Tricyclic Unit Of HimbacineSCHERING CORP·Filed 2007·Application pending·0 cites
- 4147US2025213573A1Pharmaceutical composition comprising jak inhibitor, preparation method therefor and use thereofBEIJING MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 4245US7897601B2Cannabinoid receptor modulatorsINTERVET INC·Filed 2007·Granted Mar 1, 2011·0 cites·67 claims
- 4345US2023192653A1Novel Therapeutic MethodsGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 4443US2012157403A1Bicyclic and tricyclic derivatives as thrombin receptor antagonistsCHACKALAMANNIL SAMUEL·Filed 2012·Application pending·0 cites
- 4542US11066413B2Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereofGUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD·Filed 2018·Granted Jul 20, 2021·0 cites·23 claims
- 4641USD509828SFinger mouseWANG YUGUANG·Filed 2004·Granted Sep 20, 2005·5 cites·1 claims
- 4738US2006007152A1Computer finger mouseWANG YUGUANG·Filed 2005·Application pending·0 cites
- 4837US2013102605A1Inhibitors of akt activityLIANG PENG·Filed 2011·Application pending·0 cites
- 4932US9487506B2Mineralocorticoid receptor antagonistsLAN PING·Filed 2012·Granted Nov 8, 2016·0 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Yuguang Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →